Full text
Earnings transcript
Read the complete earnings call transcript.
ACRS
Aclaris Therapeutics, Inc.
$4.3
-0.06
(-1.38%)
| Exchange: | NASDAQ |
| Market Cap: | 518.559M |
| Shares Outstanding: | 42.539M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Neal S. Walker | |||||
| Full Time Employees: | 61 | |||||
| Address: |
| |||||
| Website: | https://www.aclaristx.com |
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company’s operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company’s pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 31,249 | 18,720 | 7,826 |
| Gross Profit | 13,168 | 15,928 | 5,735 |
| EBITDA | -115,451 | -51,720 | -64,469 |
| Operating Income | -97,357 | -141,932 | -76,375 |
| Net Income | -88,481 | -132,065 | -64,923 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 197,405 | 220,327 | 160,460 |
| Total Liabilities | 40,226 | 64,773 | 57,378 |
| Total Stockholders Equity | 157,179 | 155,554 | 103,082 |
| Total Debt | 426 | 0 | 2,116 |
| Cash and Cash Equivalents | 39,878 | 24,570 | 19,960 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -78,325 | -20,075 | -47,113 |
| Capital Expenditure | -1,309 | -121 | -111 |
| Free Cash Flow | -79,634 | -20,196 | -47,113 |
| Net Income | -88,481 | -132,065 | -64,923 |
| Net Change in Cash | -5,399 | -15,308 | -4,610 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 35,619.528 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 186,341.019 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 114,380.667 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | -186,341.019 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | -35,619.528 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | -114,380.667 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | -152,374.176 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | -8,787.390 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | -83,820.516 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 66,444.369 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 347,598.976 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 213,364.738 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | -0.680 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | -0.070 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | -1.240 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 6 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 5 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about ACRS valuation
Is Aclaris Therapeutics, Inc. (ACRS) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Aclaris Therapeutics, Inc. (ACRS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is ACRS a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ACRS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is ACRS’s P/E ratio?
You can see ACRS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for ACRS?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is ACRS a good long-term investment?
Whether ACRS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
ACRS
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-1.38
Trading Metrics:
| Open: | 4.41 | Previous Close: | 4.36 | |
| Day Low: | 4.22 | Day High: | 4.47 | |
| Year Low: | 1.34 | Year High: | 5.15 | |
| Price Avg 50: | 4.36 | Price Avg 200: | 3.14 | |
| Volume: | 1M | Average Volume: | 1.762M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeCould not create stock discussion for ACRS
